Publication: Serum cardiac troponin T in unstable angina pectoris patients
Issued Date
2000-11-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-0034328493
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.83, No.SUPPL. 2 (2000)
Suggested Citation
Wattana Leowattana, Nithi Mahanonda, Kiertijai Bhuripanyo, Sasikant Pokum, Sudcharee Kiartivich Serum cardiac troponin T in unstable angina pectoris patients. Journal of the Medical Association of Thailand. Vol.83, No.SUPPL. 2 (2000). Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/26137
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Serum cardiac troponin T in unstable angina pectoris patients
Other Contributor(s)
Abstract
Cardiac troponin T (cTnT) is a regulatory contractile protein not normally found in blood, Its detection in the circulation has been shown to be a sensitive and specific marker for myocardial cell damage. In this study, we used a second-generation enzyme immunoassay for cTnT to determine whether its presence in the serum of patients with unstable angina was a prognostic indicator. Thirty patients with unstable angina peetoris (UAP) and 30 patients with Q-wave acute myocardial infarction (AMI) were screened for serum CK-MB activity and cTnT at 6, 12, 24 and 48 hours after the onset of chest pain, All of the mean concentrations of CK-MB activity determined in UAP patients were less than the upper limit of normal (25 U/L). Meanwhile, the mean concentration of cTnT at 6, 12, 24 and 48 hours after onset of chest pain were higher than the cutoff values (0,1 μg/L), We found that one third of UAP patients had serum cTnT at the time of admission more than 0.1 μg/L and that these groups of patients were associated with a high risk for cardiac events. Our results suggested that patients with elevated serum cTnT could be considered as high-risk patients for developing myocardial infarction, Patients with normal cTnT levels and a low or intermediate clinical risk could be stabilized and further stratified noninvasively,.
